Antiestrogen therapies, such as selective estrogen receptor (ER) modulators (SERMs) like tamoxifen, selective ER degraders like fulvestrant, aromatase inhibitors (AIs), and luteinizing hormone-releasing hormone agonists, are currently available and improve clinical outcomes in ERα-positive breast cancer patients. The gene discussed is ESR1; the disease is breast carcinoma.